ARDX · Ardelyx, Inc. · Webcasts, Transcripts & Audio
$3.09
-0.03 (-0.96%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$776.74M
Shares
251.37M
Volume · Nov 13
2.38M
Avg daily vol (3M)
4.39M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Ardelyx, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Ardelyx, Inc. (ARDX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-03
Ardelyx, Inc. (ARDX) Q3 2026 Earnings Call Transcript
Revenue
$127.66M
▲ 15.7% YoY Diluted EPS
$0.00
Gross margin
96.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
Ardelyx, Inc. (ARDX) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
Positive tone
Exposa (XPHOZA) growth and market opportunity
Ibsrela payer access hurdles and new patient starts
Revenue growth and Q2 record results
Revenue
$120.88M
▲ 23.8% YoY Diluted EPS
$-0.07
Gross margin
95.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Ardelyx, Inc. (ARDX) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Revenue
$94.47M
▲ 27.5% YoY Diluted EPS
$-0.15
Gross margin
94.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Confident tone
IBSRELA commercial growth
CIC label expansion (Phase III)
Next-generation pipeline (RDX-10531)
Revenue
$125.22M*
▲ 7.8% YoY Gross margin
91.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript
Confident tone
IBSRELA commercial momentum
XPHOZAH commercial performance
Pipeline development with ARDX-10531
Revenue
$110.33M
▲ 12.3% YoY Diluted EPS
$0.00
Gross margin
96.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript
Confident tone
Deliberate withholding of XPHOZAH guidance
Raised IBSRELA full-year guidance
XPHOZAH market dynamics and growth
Revenue
$97.66M
▲ 33.4% YoY Diluted EPS
$-0.08
Gross margin
87.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript
Confident tone
IBSRELA commercial performance
XPHOZAH commercial performance
XPHOZAH long-term opportunity
Revenue
$74.11M
▲ 61% YoY Diluted EPS
$-0.17
Gross margin
83.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript
Confident tone
$750 million XPHOZAH growth ambition
XPHOZAH launch and CMS coverage change
IBSRELA commercial momentum
Revenue
$116.13M*
▲ 237.9% YoY Gross margin
84.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript
Positive tone
XPHOZAH launch momentum
IBSRELA growth and field force expansion
Medicare reimbursement/CMS bundle risk
Revenue
$98.24M
▲ 74.2% YoY Diluted EPS
$0.00
▼ 100% YoY Gross margin
84.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Ardelyx, Inc. (ARDX) Q2 2024 Earnings Call Transcript
Confident tone
XPHOZAH launch momentum
IBSRELA commercial growth
CMS bundle / oral-only policy risk
Revenue
$73.22M
▲ 227.9% YoY Diluted EPS
$-0.07
Gross margin
87.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Ardelyx, Inc. (ARDX) Q1 2024 Earnings Call Transcript
Confident tone
XPHOZAH launch performance
IBSRELA commercial growth
Phosphate management unmet need
Revenue
$46.02M
▲ 304.8% YoY Diluted EPS
$-0.11
Gross margin
84.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Ardelyx, Inc. (ARDX) Q4 2023 Earnings Call Transcript
Confident tone
XPHOZAH launch and uptake
IBSRELA commercial momentum
Payer access and prior authorization
Revenue
$34.36M*
▼ 22.2% YoY Gross margin
85.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Ardelyx, Inc. (ARDX) Q3 2023 Earnings Call Transcript
Revenue
$56.39M
▲ 1031% YoY Diluted EPS
$0.03
Gross margin
86.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Ardelyx, Inc. (ARDX) Q2 2023 Earnings Call Transcript
Revenue
$22.33M
▲ 784.1% YoY Diluted EPS
$-0.08
Gross margin
84.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Ardelyx, Inc. (ARDX) Q1 2023 Earnings Call Transcript
Revenue
$11.37M
▲ 2329.3% YoY Diluted EPS
$-0.13
Gross margin
86.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Ardelyx, Inc. (ARDX) Q4 2022 Earnings Call Transcript
Revenue
$44.18M*
▲ 4193.3% YoY Gross margin
92.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Ardelyx, Inc. (ARDX) Q3 2022 Earnings Call Transcript
Revenue
$4.99M
▲ 325.1% YoY Diluted EPS
$-0.14
Gross margin
85.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Ardelyx, Inc. (ARDX) Q2 2022 Earnings Call Transcript
Revenue
$2.53M
▲ 92.4% YoY Diluted EPS
$-0.19
Gross margin
94.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Ardelyx, Inc. (ARDX) Q1 2022 Earnings Call Transcript
Revenue
$468,000
▼ 92.9% YoY Diluted EPS
$-0.21
Gross margin
81.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Ardelyx, Inc. (ARDX) Q4 2021 Earnings Call Transcript
Revenue
$1.03M*
▼ 43.1% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–22 of 22 webcasts
Key facts
CIK
1437402
CUSIP
039697107
13F (30d)
178 filings
162 filers
Visit website
Investor relations